Genomic alterations in the tumor and circulation of pancreatic cancer patients
Pancreatic adenocarcinoma has the worst overall mortality of any solid tumor, with only 7% of patients surviving after 5 years. To evaluate the clinical implications of genomic alterations in this low cellularity tumor type, we deeply sequenced the genomes of 101 enriched pancreatic adenocarcinomas from patients who underwent potentially curative resections and used non-invasive approaches to examine tumor specific mutations in the circulation of these patients. These analyses revealed somatic mutations in chromatin regulating genes including MLL and ARID1A in 20% of patients that were associated with improved survival. Liquid biopsy analyses of cell free plasma DNA revealed that 43% of patients with localized disease had detectable circulating tumor DNA (ctDNA) in their blood at the time of diagnosis. Detection of ctDNA after resection predicted clinical relapse and poor outcome, and disease recurrence by ctDNA was detected 6.5 months earlier than with standard CT imaging.
1. A method for testing and treating a human comprising:
identifying the presence of cell-free tumor DNA in a plasma sample of a human collected at the time of diagnosis of a pancreatic adenocarcinoma, wherein the cell-free tumor DNA contains a somatic mutation present in the pancreatic adenocarcinoma selected from the group consisting of:
chr7_151490485-
3704V > L
Substitution
Nonsynonymous
151490485_C_G
coding;
chr7_151515732-
Substitution
Splice site donor;
151515732_C_T
chr7_151576224-
743P > L
Substitution
Nonsynonymous
151576224_G_A
coding;
chr7_151476195-
4584R > W
Substitution
Nonsynonymous
151476195_G_A
coding;
chr7_l51686622-
Insertion
Frameshift;
151686622_TC
chr7_151601824-
Insertion
Frameshift; and
151601824_T
chr7_151510210-
1890R > X
Substitution
Nonsense;
151510210_G_A
wherein the somatic mutation is with respect to the reference human genome assembly hg18; and
performing surgery to remove the pancreatic adenocarcinoma when the presence of the cell-free tumor DNA containing the somatic mutation is identified in the plasma sample.
2. The method of claim 1 wherein the somatic mutation is a missense mutation or a truncating mutation.
3. A method for testing and treating a human comprising:
identifying the presence of cell-free tumor DNA in a plasma sample of a human collected after surgical resection of a pancreatic adenocarcinoma, wherein the cell-free tumor DNA contains a somatic mutation present in the pancreatic adenocarcinoma selected from the group consisting of:
chr7_151490485-
3704V > L
Substitution
Nonsynonymous
151490485_C_G
coding;
chr7_151515732-
Substitution
Splice site donor;
151515732_C_T
chr7_151576224-
743P > L
Substitution
Nonsynonymous
151576224_G_A
coding;
chr7_151476195-
4584R > W
Substitution
Nonsynonymous
151476195_G_A
coding;
chr7_151686622-
Insertion
Frameshift;
151686622_TC
chr12_47731362-
Deletion
Frameshift;
47731362_G_
chr7_151601824-
Insertion
Frameshift; and
151601824_T
chr7_151510210-
1890R > X
Substitution
Nonsense;
151510210_G_A
wherein the somatic mutation is with respect to the reference human genome assembly hg18; and
performing surgery to remove the pancreatic adenocarcinoma when the presence of the cell-free tumor DNA containing the somatic mutation is identified in the plasma sample.
4. The method of claim 1 , wherein the identifying is performed using a nucleic acid hybridization method.
5. The method of claim 1 , wherein the identifying is performed using a nucleic acid amplification method.
6. The method of claim 1 , wherein the identifying is performed using a nucleic acid sequencing method.
7. The method of claim 3 , wherein the identifying is performed using a nucleic acid hybridization method.
8. The method of claim 3 , wherein the identifying is performed using a nucleic acid amplification method.
9. The method of claim 3 , wherein the identifying is performed using a nucleic acid sequencing method.